Date: Wed, 15 Jan 2003 04:20:31 -2000 From: "Linda" <killind@explorer.com.hk> To: <fdowell5@excite.com> Cc: <say_whatever@yahoo.com>, <brochure@dandyweb.com>, <cshields@netdoor.com>, <tvgidus@earthlink.net>, <stace@kestok.com>, <santa@operationletterstosanta.com>, <freebsd-jobs@freebsd.org> Subject: Remember18545 Message-ID: <00004ffc074c$00006032$00002092@vx-t.itn.is>
next in thread | raw e-mail | index | archive | help
BioCurex PRESS RELEASE Source: BioCurex, Inc. January 9, 2003 OTCBB Listed BioTech Companies BOCX & RJVN - Creating a Non-Toxic Therapeutic Antibody Cancer Treatment That May Arrest Development and Replication of Cancerous Cells. Rancho Santa Margarita, Calif., January 9, 2003 BioCurex, Inc., (OTC BB:BOCX), Announces further developments relating to its licensing agreement with BioKinetix, a company being acquired by RJV Networks, Inc., (OTC BB : RJVN). BioCurex and RJV networks (through Biokinetix) are behind the development of a new therapeutic product, which experts believe will arrest the development of and replication of cancerous cells that cause the growth of malignant tumors. BOCX's proprietary technology has identified a New Widespread Cancer marker Molecule named RECAF. Cancer "markers" are molecules that appear on cancer cells but not on normal cells and have been hailed as The Holy Grail of cancer research since they can be used to detect (diagnose) and then specifically target cancer cells (therapy) - offering the potential to provide treatment of cancer by delivering antibodies to the targeted cancerous cells. RJVN and BioKinetics have proprietary technology for developing "superantibodies", an enhancement of antibody technology that makes ordinary antibodies much more lethal. The combination of anti-RECAF antibodies from BioCurex with the superantibody technology from RJVN - BioKinetics is expected to produce a powerful therapeutic agent to combat most types of cancer. If the antibodies prove to be cancer cell specific, it is unlikely that there would be any adverse side effects. This lack of toxicity should accelerate testing and approval process. Dr. Moro, President of Biocurex stated: "Our ultimate goal is to fight cancer. We have the cancer marker that identifies the cancer cells and RJV Networks-BioKinetix has the superantibody technology to kill them. It is only natural that we join forces in the battle against this horrible disease. I see tremendous potential for success in this joint effort. Dr. John Todd, President of BioKinetix Corporation stated that Bio Kinetix Corporation's mission is to acquire intellectual property rights for existing products and intellectual property. Then, through a series of collaborative relationships, we will facilitate the development of a new generation of monoclonal antibodies (termed "Superantibodies), which will have a significantly improved therapeutic potency as anticancer agents. BioCurex, Inc. Richard Moro, President RJV Networks-BioKinetix Grant Young For more info see RJVN and BOCX in the news. You can also see this Press Release at Yahoo Finance biz.yahoo.com/pz/030109/35412.html You can also look them up by their symbols: OTC BB:BOCX or OTC BB : RJVN **** Special Financial-Stock Opt-in mailing list Offer **** As a member of our special opt-in mailing list, you will be among the first to receive up to the minute information regarding the companies we profile above as well as a free 10-day trial to a website with real-time Level II quotes, research reports, OTC BB promo / syndication calendar, trading chat rooms, full threading message boards, along with many other valuable and free investment tools not readily available to the general public. This is an incredible opportunity! Just click the link below to send us an email, and you will be immediately added to our Opt-in list. Please be sure that "opt-in" is in the subject line of the email. If opt-in is not in the subject line you will not be added. MailTo:six471@excite.com?Subject=Opt-In Thank you. **See Removal instructions below ***********************Disclaimer******************** Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Equity Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. In compliance with the Securities Act of 1933, Section 17(b), Emerging Stock Alert discloses the receipt of 125,000 unrestricted shares of RJVN from a third party for the publication of this report. Be aware of an inherent conflict of interest resulting from such compensation due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. All factual information in this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and Market Guide. Emerging Equity Alert believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms. ****** Advertising Disclaimer ****** We are an Internet Advertising Company and have received a monetary payment for this mailing service. We hold no stocks and have no personal interest in this company whatsoever. We are simply being paid to perform a service. This message is a copy of a BioCurex press release. ****** Removal Instructions ****** This message has been sent to you in compliance with our strict anti-abuse regulations. We will continue to bring you valuable offers on the products and services that interest you most. If you do not wish to receive further mailings, please click below. We respect all removal requests. To be removed immediately from our mailing lists just click on the link below: MailTo:fax772@excite.com?Subject=expunge . Be sure that "purge-me" is in the subject line of the email prior to sending it. **************************************************************** *************************************************************** To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-jobs" in the body of the message
Want to link to this message? Use this URL: <https://mail-archive.FreeBSD.org/cgi/mid.cgi?00004ffc074c$00006032$00002092>